Publications and presentations from our work

2026 Skin-Specific Outcomes of Brepocitinib in Patients With Dermatomyositis – Secondary Analysis of a Phase 3 Randomized Clinical Trial JAMA Dermatology ↗ (opens in a new tab) 2026 A Phase 3 Trial of Brepocitinib in Dermatomyositis The New England Journal of Medicine ↗ (opens in a new tab) 2025 Brepocitinib Inhibits Key Pathogenic Cytokine Signaling in Dermatomyositis Patients American College of Rheumatology (ACR) 2025 — poster presentation ↗ (opens in a new tab) 2025 Patient Reported Physical Function, Mental Health, and Treatment Patterns in Dermatomyositis: Survey Results From a Cross-Sectional Study of Adult Dermatomyositis Patients BMC Rheumatology ↗ (opens in a new tab) 2024 Brepocitinib, a Selective TYK2/JAK1 Inhibitor Under Evaluation for the Treatment of Dermatomyositis, Reduces Inflammatory Cytokine Signaling and Interferon-Induced Apoptosis in Primary Human Epidermal Keratinocytes American College of Rheumatology (ACR) 2024 — poster presentation ↗ (opens in a new tab) 2024 Brepocitinib, A Potent and Selective TYK2/JAK1 Inhibitor: Scientific and Clinical Rationale for Dermatomyositis Clinical and Experimental Rheumatology ↗ (opens in a new tab) 2023 Brepocitinib Prevents Type-I Interferon Induced Damage in Cultured Myocytes and Endothelial Cells Indicating a Potential Role in the Treatment of Dermatomyositis American College of Rheumatology (ACR) 2023 — poster presentation ↗ (opens in a new tab) 2022 Brepocitinib for the Treatment of Dermatomyositis: Pharmacologic and Clinical Rationale American College of Rheumatology (ACR) 2022 — poster presentation ↗ (opens in a new tab) 2022 Use of Janus Kinase Inhibitors in Dermatomyositis: A Systematic Literature Review Clinical and Experimental Rheumatology ↗ (opens in a new tab)